Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1778: MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer

View through CrossRef
Abstract Introduction: Prostate cancer (PCa) is a leading cause of cancer death, and there are significant racial disparities in patient outcomes. Non-coding RNAs (lncRNAs) MALAT1 and TUG1 are recognised for their roles in oncogenic pathways. Their precise interacting mechanisms with splicing factors and splicing factor kinases is understudied. Aim: This study aims to map the biological pathways influenced by TUG1, MALAT1 in response to SRPK1 inhibitor prostate cancer cells Materials and Methods: Bioinformatics tools LncSEA 2.0, STRING, DAVID and Reactome were used to analyse the interactions between MALAT1, TUG1 and relevant miRNAs and their target genes. Resozuring cell viability assay was used to measure PCa cell viability (PC-3 cells vs HEK) in response to Sphinx31 at 24hrs and 48hrs. Next, RT-qPCR was used to measure gene expression levels of the lncRNAs. Results and Discussion: MALAT1 and TUG1 act as competing endogenous RNAs (ceRNAs) to sponge miRNAs that regulate critical tumour proliferation and migration genes, including PTEN and BCL2. SRPK1 regulates splicing factors to enhance tumour aggressiveness. The MALAT1-miR-125b-BCL2 and TUG1-miR-29b-PTEN axes are critical pathways for PCa progression, especially in advanced stages. Sphinx31 is cytotoxic in a time dependent manner to the PCa cells, while the 2 lncRNAs expression is elevated in PCa cells prior to Sphinx31 treatment. Conclusion: Targeting lncRNA-miRNA networks and splicing factor interactions, especially MALAT1 and SRPK1, is a potential therapeutic target for PCa. Citation Format: Linomtha Gabada, Zodwa Dlamini, Rahaba Makgotso Marima. MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1778.
American Association for Cancer Research (AACR)
Title: Abstract 1778: MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer
Description:
Abstract Introduction: Prostate cancer (PCa) is a leading cause of cancer death, and there are significant racial disparities in patient outcomes.
Non-coding RNAs (lncRNAs) MALAT1 and TUG1 are recognised for their roles in oncogenic pathways.
Their precise interacting mechanisms with splicing factors and splicing factor kinases is understudied.
Aim: This study aims to map the biological pathways influenced by TUG1, MALAT1 in response to SRPK1 inhibitor prostate cancer cells Materials and Methods: Bioinformatics tools LncSEA 2.
0, STRING, DAVID and Reactome were used to analyse the interactions between MALAT1, TUG1 and relevant miRNAs and their target genes.
Resozuring cell viability assay was used to measure PCa cell viability (PC-3 cells vs HEK) in response to Sphinx31 at 24hrs and 48hrs.
Next, RT-qPCR was used to measure gene expression levels of the lncRNAs.
Results and Discussion: MALAT1 and TUG1 act as competing endogenous RNAs (ceRNAs) to sponge miRNAs that regulate critical tumour proliferation and migration genes, including PTEN and BCL2.
SRPK1 regulates splicing factors to enhance tumour aggressiveness.
The MALAT1-miR-125b-BCL2 and TUG1-miR-29b-PTEN axes are critical pathways for PCa progression, especially in advanced stages.
Sphinx31 is cytotoxic in a time dependent manner to the PCa cells, while the 2 lncRNAs expression is elevated in PCa cells prior to Sphinx31 treatment.
Conclusion: Targeting lncRNA-miRNA networks and splicing factor interactions, especially MALAT1 and SRPK1, is a potential therapeutic target for PCa.
Citation Format: Linomtha Gabada, Zodwa Dlamini, Rahaba Makgotso Marima.
MALAT1 and TUG1 long non-coding RNAs signalling mechanisms in response to SRPK1 inhibitor in prostate cancer [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1778.

Related Results

Abstract MIP-057: TARGETING THE LONG–NONCODING RNA MALAT1 IN OVARIAN CANCER
Abstract MIP-057: TARGETING THE LONG–NONCODING RNA MALAT1 IN OVARIAN CANCER
Abstract PURPOSE: Ovarian cancer metastasizes via direct seeding, whereby cells must resist anoikis (detachment-induced cell death) in the peritoneal cavity before i...
Abstract 1835: NFATC1 regulates the long non-coding RNA MALAT1 in breast cancer
Abstract 1835: NFATC1 regulates the long non-coding RNA MALAT1 in breast cancer
Abstract Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a long non-coding RNA overexpressed in many solid tumors such as breast, colorectal, live...
Pathophysiological Functions of the lncRNA TUG1
Pathophysiological Functions of the lncRNA TUG1
Background: Long non-coding RNAs (lncRNAs) with little or no coding capacity are associated with a plethora of cellular functions, participating in various biological processes. Cu...
The E1^E4 Protein of Human Papillomavirus Interacts with the Serine-Arginine-Specific Protein Kinase SRPK1
The E1^E4 Protein of Human Papillomavirus Interacts with the Serine-Arginine-Specific Protein Kinase SRPK1
ABSTRACT Human papillomavirus (HPV) infections of the squamous epithelium are associated with high-level expression of the E1^E4 protein during the productive phase of in...
Clinical Implications of SRPK1 Expression in Human Tumours: A Comprehensive Pan-Cancer Analysis Based on Multi-Omics Databases
Clinical Implications of SRPK1 Expression in Human Tumours: A Comprehensive Pan-Cancer Analysis Based on Multi-Omics Databases
Abstract Serine/arginine-rich protein kinase 1 (SRPK1), which primarily regulates alternative splicing (AS), has been implicated in various malignancies. However, t...
Data from Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer
Data from Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer
<div>Abstract<p>Overcoming drug resistance is one of the biggest challenges in cancer chemotherapy. In this study, we examine whether targeting the long noncoding RNA t...
Notch regulated long non-coding RNA TUG1 regulates smooth muscle cell differentiation in aortic aneurysm
Notch regulated long non-coding RNA TUG1 regulates smooth muscle cell differentiation in aortic aneurysm
Abstract Abdominal Aortic Aneurysms (AAAs) are asymptomatic vascular diseases with life threatening outcomes. Smooth-muscle cell (SMC) dysfunctio...
Abstract 1825: The inhibitory effect of long non-coding RNA MALAT1 on Smads signaling pathway.
Abstract 1825: The inhibitory effect of long non-coding RNA MALAT1 on Smads signaling pathway.
Abstract Long non-coding RNA (lncRNA) is arbitrarily defined as RNA longer than 200 bases that does not encode mRNA, rRNA or tRNA. LncRNAs are involved in almost eve...

Back to Top